Break the Stigma, Save a Life
While gains have been made in reducing stigma around certain conditions, like depression and obesity, little progress has been made in removing the stigma around substance use disorders. The public and even health care providers continue to blame patients for their disease even though there is clear consensus that addiction is a complex brain disorder and not the result of moral weakness and flawed character.
When people with addiction are stigmatized and rejected, especially by those within healthcare, it only contributes to the vicious cycle that entrenches their disease.
This activity will shine the light on shame, stigma, and MOUD (medication for opioid use disorder) in the light of harm reduction as well as the importance of meeting patients where they are.
At the end of this session, learners should be able to:
Enhance knowledge about stigma surrounding substance use disorder and its treatment
Reflect on how stigma and racism have influenced drug policy in the U.S., including recent responses to the opioid epidemic
Recall the meaning of harm reduction and related concepts
Identify ways to reduce harm related to substance use
Identify ways to promote health and dignity with people who use drugs
This activity is intended for family medicine physicians, and other primary care providers and clinicians caring for patients with substance use disorder.
Participation and Credit:
Learners must register to participate in and receive credit for this online educational activity. Read the target audience, learning objectives, and author disclosures. Study the educational content online and complete the activity evaluation. Your certificate will be available to you as a downloadable link. You may print the certificate, but you cannot alter it. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Unlabeled Use Disclosure:
This activity will not include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), and the curriculum clearly indicates this fact.
This activity is sponsored by the California Academy of Family Physicians and supported by the National Institute on Drug Abuse (NIDA) and the California Department of Health Care Service (DHCS).
There is no charge for this activity.
CAFP policy and California state law requires that each learning activity have elements of cultural and linguistic proficiency included in the content. The definition of cultural and linguistic competency is the ability and readiness of health care providers and health organizations to humbly and respectfully demonstrate, effectively communicate, and tailor delivery of care to patients with diverse values, beliefs, identities, and behaviors, in order to meet patients’ social, cultural, and linguistic needs as it relates to patient health. This activity meets these requirements.
CAFP policy and California state law requires that all CME activities comprising a patient care element include either (1) examples of how implicit bias affects perceptions and treatment decisions of physicians and surgeons, leading to disparities in health outcomes and/or (2) strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics. This activity meets these requirements.
The California Academy of Family Physicians (CAFP) is committed to protecting the privacy of its members and customers. CAFP maintains safeguards to store and secure information it has about members and customers. The safeguards may be physical, electronic or procedural. For more information, contact firstname.lastname@example.org.
For questions regarding the content of this activity or for technical assistance, contact email@example.com.
The CAFP has made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the learner is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Approval of credit for this continuing education program does not imply endorsement by CAFP of any product or manufacturer identified.
Any medications or treatment methods suggested in this CME activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.
© 2023 California Academy of Family Physicians. No part of this activity may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.
Sky Lee, MD
Dr. Lee’s primary interests are to improve care and access for vulnerable populations, to empower both patients and providers to be advocates for their communities and to dismantle white supremacy within ourselves and in medicine. She’s been on the faculty of UC Davis Medical Center, and has worked with the California Bridge program. She currently works with people who are incarcerated.
Mary Kathryn MK Orsulak, MD
Dr. Orsulak is passionate about decreasing barriers to primary care and integrating harm reduction when providing patient care. She serves patients at the Sacramento County Primary Care Clinic, Mercy Clinic at Loaves and Fishes, and the Sacramento County Department of Public Health Sexual Health Clinic. Dr. Orsulak is an attending on the inpatient UC Davis Substance Use Intervention Team and working on projects to improve access and quality of care for people living outside in Sacramento.
Conflict of Interest Statements:
The Committee on Continuing Professional Development and CME will be responsible for mitigating any relevant financial relationships disclosed by an individual who may have influence on content, who have served as faculty, or who may produce CME/CPD content for the CAFP. Mitigation may include learner notification, peer review of content before presentation, requirement of EB-CME, changing topics, or even dismissing a potential faculty member.
It is the policy of the CAFP to ensure independence, balance, objectivity, scientific rigor, and integrity in all continuing education activities. All individuals with potential to influence the content of this program have submitted Disclosure of Interest declarations that have been reviewed according to policy. Learner notification of declarations is below. All individuals with relevant financial relationships with ineligible companies have been contacted by CAFP staff or CCPD members, and issues of conflict have been discussed and mitigated.
All faculty declare that they have no financial relationships with ineligible companies to disclose.
The following planners have no financial relationships with ineligible companies to disclose: Jerri Davis, Laurie Isenberg
1.00 AAFP Prescribed Credit
The AAFP has reviewed Call to Action: The Time for Treating Substance Use Disorder Is Now, and deemed it acceptable for 2.75 AAFP Prescribed credits. Term of approval is from 02/22/2023 to 02/22/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This session, Break the Stigma, Save a Life, is approved for 1.00 AAFP Prescribed credit.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™
toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
- 1.00 AAFP Prescribed
- 1.00 AMA PRA Category 1 Credit™